针对优势慢乙肝患者联合抗病毒治疗HBsAg基线水平的探索  

Exploring the Baseline Level of HBsAg in Patients with Superior Chronic Hepatitis B Combined with Antiviral Therapy

作　　者：高倩[1] 贾士杰[1] 谭颖[2] 范慧敏[1] 关玉娟[2] 谭行华[1] GAO Qian;JIA Shijie;TAN Ying;FAN Huimin;GUAN Yujuan;TAN Xinghua(Department of Liver Diseases of Integrated Traditional Chinese and Western Medicine,Guangzhou Eighth People's Hospital,Guangzhou,Guangdong Province,510060 China;Department of Liver Diseases,Guangzhou Eighth People's Hospital,Guangzhou,Guangdong Province,510060 China)

机构地区：[1]广州市第八人民医院中西医结合肝病科,广东广州510060 [2]广州市第八人民医院肝病科,广东广州510060

出　　处：《系统医学》2021年第9期29-31,共3页Systems Medicine

基　　金：广州市医药卫生科技项目(20172A 010016)。

摘　　要：目的探索恩替卡韦(ETV)经治的优势慢乙肝患者联合聚乙二醇干扰素(Peg-IFN)抗病毒治疗的最佳HBsAg基线水平。方法选取该院于2017年6月—2020年3月收治的38例HBeAg阴性的ETV经治患者38例为研究对象,根据HBsAg定量分为A组<100 IU/mL 16例、B组100~500 IU/mL 11例、C组>500 IU/mL 11例3组,分别观察治疗12周、24周、48周时各组HBsAg定量变化情况,比较各组间HBsAg清除率及HBsAg血清学转换率差异。结果A、B、C组在基线、治疗12、24、48周时HBsAg定量两两比较,差异有统计学意义(P<0.05)。各组间相同时间点对比,差异有统计学意义(P<0.05)。HBsAg清除率上3组之间两两对比,A、C组24、48周的占比分别为75.0%、81.3%和0.0%、9.1%,对比差异有统计学意义(P<0.001)。48周内HBsAg血清学转换患者人数占比A、B组差异无统计学意义(P>0.05)。结论HBsAg基线≤500 IU/mL的慢乙肝优势患者开始联合抗病毒治疗可在较短疗程内取得较高的临床治愈率。Objective To explore the advantages of entecavir(ETV)treatment of chronic hepatitis B patients combined with peg-interferon(Peg-IFN)antiviral treatment of the best HBsAg baseline level.Methods A total of 38 HBeAg-negative ETV patients treated in the hospital from June 2017 to March 2020 were selected as the research objects.According to HBsAg,they were divided into 16 cases in group A<100 IU/mL and 11 cases in group B 100-500 IU/mL,11 cases in group C>500 IU/mL,respectively,observed the quantitative changes of HBsAg in each group at 12 weeks,24 weeks,48 weeks,and compared the differences in HBsAg clearance rate and HBsAg seroconversion rate between the groups.Results A,B,and C groups had statistically significant differences in HBsAg quantitative comparison at baseline and at 12 weeks,24 weeks,and 48 weeks treatment,the difference was statistically significant(P<0.05).There were statistical differences between the groups at the same time point,the difference was statistically significant(P<0.05).The proportions of 24 weeks and 48 weeks in group A and C were 75.0%,81.3%,0.0%,and 9.1%,respectively,in the clearance rate of HBsAg among the three groups,the difference was statistically significant(P<0.001).There was no statistically significant difference in the proportion of patients with HBsAg seroconversion in groups A and B within 48 weeks(P>0.05).Conclusion The predominant patients with chronic hepatitis B whose baseline HBsAg is≤500 IU/mL begin to combine antiviral therapy to achieve a higher clinical cure rate in a shorter course of treatment.

关 键 词：慢性乙型肝炎 乙肝表面抗原 抗病毒治疗 

分 类 号：R512.6[医药卫生—内科学]